# Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

> **NCT04956640** · PHASE1,PHASE2 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 540 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Endometrial Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Biliary Tract Neoplasms

## Interventions

- **DRUG:** LY3537982
- **DRUG:** Pembrolizumab
- **DRUG:** Cetuximab
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04956640
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-19
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04956640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04956640, "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04956640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*